MYD88 and cancer: IL-33/ST2 signaling activates myeloid differentiation primary response 88 (MyD88)/interleukin-1 receptor (IL-1R) associated kinase (IRAK)/TNF receptor-associated factor 6 (TRAF6) pathway in the majority of cell types, including cancer cells, stromal cells, and immune cells.